# Salesforce Jumps on BofA Upgrade, Adobe Slides _Salesforce rose 3.1% after BofA's double upgrade to Buy while Adobe and Bristol Myers slid on downgrade and trial doubts, per Bloomberg Podcasts._ **Published:** 2026-10-17 **Source:** https://www.startuphub.ai/ai-news/public-companies/2026/salesforce-jumps-on-bofa-upgrade-adobe-slides --- [Bloomberg Podcasts](https://www.youtube.com/watch?v=Z9Suid1moWE) said Salesforce rose 3.1% to its highest intraday level since August after Bank of America double upgraded the stock to Buy from Underperform on AI resilience. BofA Upgrades SalesforceDriverdouble upgrade to Buy from Underperform on AI resilienceFrom the articleThe split leaves software investors sorting AI winners from exposed names, and Salesforce now has to prove Agentforce monetization can justify the upgrade.Price Target $285CoreFrom the article 2 mentionsBank of America raised its price target to $285 from $160, about 24% above the $229.13 level cited at the time, according to Investing.com.Enterprise Moat StrategyContextFrom the articleAvalon Pernell said on the Stock Movers Report that the call hinges on moat, with large enterprises unlikely to rip out Salesforce systems that house business logic, data and compliance workflows.enablesSalesforce Rises 3.1%OutcomeFrom the article 3 mentionsBloomberg Podcasts said Salesforce rose 3.1% to its highest intraday level since August after Bank of America double upgraded the stock to Buy from Underperform on AI resilience.BofA Upgrades SalesforceDriverdouble upgrade to Buy from Underperform on AI resilienceFrom the articleThe split leaves software investors sorting AI winners from exposed names, and Salesforce now has to prove Agentforce monetization can justify the upgrade.Adobe Down 1.8%OutcomeFrom the articleAdobe slid 1.8% after Wells Fargo double downgraded it to Underweight, with the analyst pointing to muted third quarter results and doubts about hitting full year targets without price hikes on core subscriptions, Pernell reported.Bristle Myers Falls 3%Outcomeslid to lowest level since July on trial doubtsPrice Target $285CoreFrom the article 2 mentionsBank of America raised its price target to $285 from $160, about 24% above the $229.13 level cited at the time, according to Investing.com.Enterprise Moat StrategyContextFrom the articleAvalon Pernell said on the Stock Movers Report that the call hinges on moat, with large enterprises unlikely to rip out Salesforce systems that house business logic, data and compliance workflows.Subscription Pricing PressureContextAdobe needs price hikes to hit full year targetsenablesSalesforce Rises 3.1%OutcomeFrom the article 3 mentionsBloomberg Podcasts said Salesforce rose 3.1% to its highest intraday level since August after Bank of America double upgraded the stock to Buy from Underperform on AI resilience.showsAI Resilience FocusCoreBofA upgrade hinges on AI strategy and enterprise lock-inFrom the articleBloomberg Podcasts said Salesforce rose 3.1% to its highest intraday level since August after Bank of America double upgraded the stock to Buy from Underperform on AI resilience. Bank of America raised its price target to $285 from $160, about 24% above the $229.13 level cited at the time, according to [Investing.com](https://www.investing.com/news/stock-market-news/bofa-double-upgrades-salesforce-to-buy-on-ai-strategy-nearly-doubles-target-4944274). Avalon Pernell said on the Stock Movers Report that the call hinges on moat, with large enterprises unlikely to rip out Salesforce systems that house business logic, data and compliance workflows. ![Bristol Myers Climbs, Adobe Drops, Salesforce Gains as BofA Raises to Buy on AI Strategy | Stock... - Bloomberg Podcast](https://img.youtube.com/vi/Z9Suid1moWE/maxresdefault.jpg) Bristol Myers Climbs, Adobe Drops, Salesforce Gains as BofA Raises to Buy on AI Strategy | Stock..., Bloomberg Podcast Adobe slid 1.8% after Wells Fargo double downgraded it to Underweight, with the analyst pointing to muted third quarter results and doubts about hitting full year targets without price hikes on core subscriptions, Pernell reported. Bristol Myers slid about 3% to its lowest intraday level since July after a lung disease drug met a key endpoint but showed no dose response, leaving Cantor cautious about competitiveness despite positive 60 mg data. The split leaves software investors sorting AI winners from exposed names, and Salesforce now has to prove Agentforce monetization can justify the upgrade. --- Original analysis from [startuphub.ai](https://www.startuphub.ai), the #1 AI startup directory. © StartupHub.ai. All rights reserved. You may not republish this article in full without a license. Search engines and AI research tools may crawl and summarize for reference. Bulk reproduction or model training on this content requires a license. See https://www.startuphub.ai/terms.